Johnson & Johnson at #ASH23 (Max Gelman for Endpoints News)
December 12, 2023 12:00 PM EST
R&D

J&J and Gen­mab tout first-line in­jectable Darza­lex for mul­ti­ple myelo­ma: #ASH23

Max Gelman

Senior Editor

SAN DIEGO — J&J and Gen­mab fleshed out their case Tues­day morn­ing to move their sub­cu­ta­neous ver­sion of the can­cer drug Darza­lex in­to ear­li­er lines …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times